PL3510033T3 - Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych - Google Patents
Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnychInfo
- Publication number
- PL3510033T3 PL3510033T3 PL17777966T PL17777966T PL3510033T3 PL 3510033 T3 PL3510033 T3 PL 3510033T3 PL 17777966 T PL17777966 T PL 17777966T PL 17777966 T PL17777966 T PL 17777966T PL 3510033 T3 PL3510033 T3 PL 3510033T3
- Authority
- PL
- Poland
- Prior art keywords
- toll
- inhibitors
- compositions
- compounds
- endosomal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385726P | 2016-09-09 | 2016-09-09 | |
| PCT/IB2017/055375 WO2018047081A1 (en) | 2016-09-09 | 2017-09-06 | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| EP17777966.7A EP3510033B1 (en) | 2016-09-09 | 2017-09-06 | Compounds and compositions as inhibitors of endosomal toll-like receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3510033T3 true PL3510033T3 (pl) | 2022-03-07 |
Family
ID=60001955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17777966T PL3510033T3 (pl) | 2016-09-09 | 2017-09-06 | Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10954233B2 (pl) |
| EP (2) | EP3510033B1 (pl) |
| JP (1) | JP6779371B2 (pl) |
| KR (2) | KR20190039809A (pl) |
| CN (2) | CN115215886B (pl) |
| AU (1) | AU2017323584C1 (pl) |
| CA (1) | CA3031585A1 (pl) |
| CL (1) | CL2019000588A1 (pl) |
| CO (1) | CO2019003397A2 (pl) |
| CR (1) | CR20190119A (pl) |
| CU (1) | CU24526B1 (pl) |
| CY (1) | CY1125007T1 (pl) |
| DK (1) | DK3510033T3 (pl) |
| DO (1) | DOP2019000055A (pl) |
| EA (1) | EA036880B1 (pl) |
| EC (1) | ECSP19024046A (pl) |
| ES (1) | ES2905981T3 (pl) |
| HR (1) | HRP20220144T1 (pl) |
| HU (1) | HUE057254T2 (pl) |
| IL (1) | IL265159B (pl) |
| JO (1) | JOP20190041B1 (pl) |
| LT (1) | LT3510033T (pl) |
| MA (1) | MA46196A (pl) |
| MX (1) | MX382383B (pl) |
| MY (1) | MY194813A (pl) |
| NZ (1) | NZ750781A (pl) |
| PE (1) | PE20190732A1 (pl) |
| PH (1) | PH12019500161A1 (pl) |
| PL (1) | PL3510033T3 (pl) |
| PT (1) | PT3510033T (pl) |
| RS (1) | RS62913B1 (pl) |
| RU (1) | RU2759678C2 (pl) |
| SG (1) | SG11201900482SA (pl) |
| SI (1) | SI3510033T1 (pl) |
| WO (1) | WO2018047081A1 (pl) |
| ZA (1) | ZA201900227B (pl) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3929196T3 (da) | 2013-09-24 | 2023-09-25 | Fujifilm Corp | Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf |
| ES2990113T3 (es) | 2016-07-07 | 2024-11-28 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Conjugados de adyuvantes de anticuerpos |
| MX382383B (es) | 2016-09-09 | 2025-03-13 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo toll |
| CN117402852A (zh) | 2016-10-14 | 2024-01-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| JP2021507889A (ja) | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| BR112020019814A2 (pt) | 2018-03-30 | 2021-01-05 | Incyte Corporation | Tratamento de hidradenite supurativa usando inibidores jak |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| JP7407740B2 (ja) * | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| SG11202011137SA (en) | 2018-06-05 | 2020-12-30 | Hoffmann La Roche | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112584903B (zh) | 2018-07-23 | 2025-12-23 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的哌嗪化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
| JP2022502353A (ja) | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のための新規の環状アミジン化合物 |
| EP3847173B1 (en) | 2018-09-06 | 2023-04-12 | F. Hoffmann-La Roche AG | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| CN112673003A (zh) * | 2018-09-07 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型吡咯烷胺化合物 |
| BR112021008255A2 (pt) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | compostos de 6-azabenzimidazol substituídos como inibidores de hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| AU2020231201B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2020240272A1 (en) * | 2019-05-31 | 2020-12-03 | Dr.Reddy's Institute Of Life Sciences | Preparation of novel 1 h-pyrazolo[4,3-d]pyrimidines, their compositions, synthesis and methods of using them for treating tuberculosis |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4037708B1 (en) | 2019-09-30 | 2024-09-18 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| US12421240B2 (en) | 2019-10-31 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| US12486273B2 (en) | 2019-11-19 | 2025-12-02 | Hoffmann-La Roche Inc. | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| EP4061821B1 (en) | 2019-11-20 | 2025-08-06 | F. Hoffmann-La Roche AG | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20230140430A1 (en) * | 2020-01-27 | 2023-05-04 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097105A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP2023533807A (ja) * | 2020-07-14 | 2023-08-04 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
| KR102513463B1 (ko) | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| WO2022221642A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| US12070455B2 (en) | 2021-09-10 | 2024-08-27 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN118076604A (zh) | 2021-09-24 | 2024-05-24 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物 |
| WO2023135505A1 (en) | 2022-01-11 | 2023-07-20 | Novartis Ag | Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| TW202544019A (zh) | 2024-05-13 | 2025-11-16 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003591A3 (cs) | 2000-08-10 | 2003-06-18 | Pharmacia Italia S. P. A. | Bicyklopyrazoly účinné jako kinázové inhibitory, způsob jejich přípravy a farmaceutické prostředky, které je obsahují |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| MXPA05009719A (es) | 2003-03-11 | 2005-10-18 | Pharmacia Italia Spa | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. |
| US20060089378A1 (en) | 2004-10-27 | 2006-04-27 | Mingde Xia | Tetrahydro-pyridinyl pyrazole cannabinoid modulators |
| WO2007022280A1 (en) * | 2005-08-16 | 2007-02-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| US20090118263A1 (en) * | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| WO2007123953A2 (en) | 2006-04-19 | 2007-11-01 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| ES2388315T3 (es) | 2007-05-04 | 2012-10-11 | Bristol-Myers Squibb Company | Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G |
| AU2008331733A1 (en) * | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta |
| US8524702B2 (en) | 2009-08-18 | 2013-09-03 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| PL2491035T3 (pl) * | 2009-10-22 | 2018-01-31 | Gilead Sciences Inc | Pochodne puryny lub deazapuryny przydatne do leczenia (między innymi) infekcji wirusowych |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| MX344478B (es) | 2010-11-19 | 2016-12-16 | Incyte Holdings Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak). |
| WO2012154608A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive mtor and pi3 kinase inhibitors and uses thereof |
| EP2723737A1 (en) | 2011-06-27 | 2014-04-30 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| EA039373B1 (ru) | 2012-02-08 | 2022-01-19 | Янссен Сайенсиз Айрлэнд Юси | Производные пиперидино-пиримидина для лечения вирусных инфекций |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| JPWO2014034719A1 (ja) | 2012-08-29 | 2016-08-08 | 興和株式会社 | Ｔｌｒ阻害作用を有するキノリン誘導体 |
| MX365114B (es) | 2012-10-10 | 2019-05-23 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. |
| TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| KR20150130398A (ko) | 2013-03-14 | 2015-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | 비시클로 [2.2.2] 산 gpr120 조절제 |
| BR112015027760A8 (pt) | 2013-05-02 | 2018-05-08 | Pfizer | derivados de imidazo-triazina como inibidores da pde10 |
| US10471139B2 (en) * | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| WO2015024021A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| EP3036102A4 (en) | 2013-08-19 | 2017-01-25 | Queen's University At Kingston | Carbene functionalized composite materials |
| CA2921880A1 (en) | 2013-08-22 | 2015-02-26 | F. Hoffmann-La Roche Ag | Alkynyl alcohols and methods of use |
| WO2015036044A1 (en) | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
| MA39034B1 (fr) * | 2013-10-14 | 2018-09-28 | Eisai R&D Man Co Ltd | Composés de quinoline sélectivement substitués |
| CA2920791C (en) | 2013-10-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| AR101106A1 (es) * | 2014-07-02 | 2016-11-23 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton |
| CN110938076B (zh) | 2014-08-15 | 2021-08-10 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| EP3233829B1 (en) * | 2014-12-18 | 2019-08-14 | Pfizer Inc | Pyrimidine and triazine derivatives and their use as axl inhibitors |
| MX383929B (es) | 2014-12-30 | 2025-03-14 | Novira Therapeutics Inc | Derivados y métodos de tratamiento de las infecciones por hepatitis b. |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| PT3268356T (pt) | 2015-03-12 | 2021-11-23 | Novartis Ag | Compostos heterocíclicos e métodos para a sua utilização |
| CN114539284A (zh) | 2016-03-16 | 2022-05-27 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| MX382383B (es) | 2016-09-09 | 2025-03-13 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo toll |
-
2017
- 2017-09-06 MX MX2019002797A patent/MX382383B/es unknown
- 2017-09-06 CU CU2019000018A patent/CU24526B1/es unknown
- 2017-09-06 CN CN202210863391.4A patent/CN115215886B/zh active Active
- 2017-09-06 ES ES17777966T patent/ES2905981T3/es active Active
- 2017-09-06 RS RS20220087A patent/RS62913B1/sr unknown
- 2017-09-06 EA EA201990657A patent/EA036880B1/ru not_active IP Right Cessation
- 2017-09-06 CN CN201780053304.6A patent/CN109641899B/zh active Active
- 2017-09-06 WO PCT/IB2017/055375 patent/WO2018047081A1/en not_active Ceased
- 2017-09-06 US US16/330,820 patent/US10954233B2/en active Active
- 2017-09-06 KR KR1020197008484A patent/KR20190039809A/ko not_active Withdrawn
- 2017-09-06 LT LTEPPCT/IB2017/055375T patent/LT3510033T/lt unknown
- 2017-09-06 KR KR1020217018684A patent/KR102411532B1/ko active Active
- 2017-09-06 HR HRP20220144TT patent/HRP20220144T1/hr unknown
- 2017-09-06 HU HUE17777966A patent/HUE057254T2/hu unknown
- 2017-09-06 AU AU2017323584A patent/AU2017323584C1/en active Active
- 2017-09-06 EP EP17777966.7A patent/EP3510033B1/en active Active
- 2017-09-06 MY MYPI2019000071A patent/MY194813A/en unknown
- 2017-09-06 MA MA046196A patent/MA46196A/fr unknown
- 2017-09-06 PL PL17777966T patent/PL3510033T3/pl unknown
- 2017-09-06 CR CR20190119A patent/CR20190119A/es unknown
- 2017-09-06 DK DK17777966.7T patent/DK3510033T3/da active
- 2017-09-06 SG SG11201900482SA patent/SG11201900482SA/en unknown
- 2017-09-06 SI SI201731065T patent/SI3510033T1/sl unknown
- 2017-09-06 EP EP21208454.5A patent/EP4059934A1/en active Pending
- 2017-09-06 PE PE2019000478A patent/PE20190732A1/es unknown
- 2017-09-06 JP JP2019513008A patent/JP6779371B2/ja active Active
- 2017-09-06 JO JOP/2019/0041A patent/JOP20190041B1/ar active
- 2017-09-06 CA CA3031585A patent/CA3031585A1/en active Pending
- 2017-09-06 PT PT177779667T patent/PT3510033T/pt unknown
- 2017-09-06 RU RU2019110157A patent/RU2759678C2/ru active
- 2017-09-06 NZ NZ750781A patent/NZ750781A/en unknown
-
2019
- 2019-01-14 ZA ZA201900227A patent/ZA201900227B/en unknown
- 2019-01-22 PH PH12019500161A patent/PH12019500161A1/en unknown
- 2019-03-04 IL IL265159A patent/IL265159B/en unknown
- 2019-03-06 DO DO2019000055A patent/DOP2019000055A/es unknown
- 2019-03-08 CL CL2019000588A patent/CL2019000588A1/es unknown
- 2019-04-05 EC ECSENADI201924046A patent/ECSP19024046A/es unknown
- 2019-04-05 CO CONC2019/0003397A patent/CO2019003397A2/es unknown
-
2020
- 2020-12-16 US US17/124,346 patent/US20210101902A1/en not_active Abandoned
-
2022
- 2022-02-22 CY CY20221100153T patent/CY1125007T1/el unknown
-
2024
- 2024-05-30 US US18/678,198 patent/US20240376099A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3510033T3 (pl) | Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| IL256393B (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| LT3436461T (lt) | Pirolotriazino junginiai kaip tam inhibitoriai | |
| EP3377059A4 (en) | INHIBITORS OF CXCR2 | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| EP3509581A4 (en) | FORMULATIONS OF (R | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| EP3347333C0 (en) | POLYMERIZATION INHIBITING COMPOSITIONS | |
| EP3356447A4 (en) | INHIBITORS OF MENACHINONE BIOSYNTHESIS | |
| PT3371152T (pt) | Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro | |
| DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
| LT3116491T (lt) | Terapiškai aktyvių junginių farmacinės kompozicijos | |
| DK3386991T3 (da) | Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3240767T3 (da) | Mikroindkapslede nitrifikationshæmmersammensætninger | |
| IL248223A0 (en) | Vaccine compositions | |
| PL3227325T3 (pl) | Selektywne kompozycje inhibitorów trans-sygnałowania il-6 | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| IL249674B (en) | Quinolizinone derivatives as pi3k inhibitors | |
| DK3137658T3 (da) | Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer | |
| IL258630B1 (en) | Formulation of l-ornithine phenylacetate | |
| DK3173071T3 (da) | Formularing af maropitant |